medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2008, Number 02

<< Back Next >>

Ginecol Obstet Mex 2008; 76 (02)

Monitoring to patients with breast cancer after multimodal treatment

Martínez PM, Flores TCB, Sánchez BC, Sánchez FE

Language: Spanish
References: 23
Page: 107-112
PDF size: 131.95 Kb.


ABSTRACT

Breast cancer is a frequent neoplasm in Latin America. Its control implies surveillance for about 10 years after diagnosis. The possibilities of metastatic disease depend on stage at diagnosis and the treatment administered to the patient. It is important that all medical centers implement their own follow-up that fits its needs. Surveillance must include physical therapy, attention to psychosocial aspects as well as treatment for toxicity, secondary effects, recurrence and second primaries. The American Society of Clinical Oncology (ASCO) includes monthly self-examination, annual mammography, office visits every three months for the first three years, and then biannual visits for the next two years and then annually. Randomized studies and the Cochrane database have proved that intensive follow-up is of no value compared with periodic appointments and annual mammography. Existing evidence suggests that postoperative surveillance of breast cancer patients is extremely expensive, time consuming and of no benefit in terms of survival. Most of recurrences present out of context from follow up visits. Thus, efficacy of routine doctor visits is questionable and a prospective study is needed to outline the adequate strategy.


REFERENCES

  1. Dershaw DD, McCormick B, Osborne MP. Detection of local recurrence after conservative therapy for breast carcinoma. Cancer 1992;70:493-6.

  2. Haffty BG, Fisher D, Beinfield M, McKhann C. Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys 1991;21:293-8.

  3. Veronesi U, Marubini E, Del Vecchio M, et al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 1995;87:19-27.

  4. Woodward WA, et al. Changes in the 2003 AJCS for breast cancer dramatically affect stage-specific survival. J Clin Oncol 2003;21:3244-8.

  5. Petrek JA, Lerner R. Lymphedema. In: Lippman ME, Morrow M, Osborne K, editors. Diseases of the breast. 2nd ed. Philadelphia: Lippincott, 2000;pp:1033-40.

  6. Pressman PI. Surgical treatment and lymphedema. Cancer 1998;83(12 suppl):2782-7.

  7. Morrel RM. Breast cancer-related lymphedema. Mayo Clin Proc 2005;80(11):1480-4.

  8. Fisher B, Anderson S. Conservative surgery for the management of invasive and non-invasive carcinoma of the breast: NSABP trials. World J Surg 1994;18:63-69.

  9. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001;344(26):1997-2008.

  10. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer: a randomized trial. National Research Council Project on breast cancer follow-up. JAMA 1994;271:1593-7.

  11. Goldhirsh A, Gelber RD, Castiglione M. Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognosis. J Clin Oncol 1988;6:1593-7.

  12. Goldhirsch A, Gelber RD, Price KN, et al. Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet 1994;343:377-81.

  13. Pisansky TM, Ingle JN, Schaid DJ, et al. Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer: impact of clinical, histopathologic, and flow cytometric factors. Cancer 1993;72:1247-60.

  14. Abner AL, Recht A, Eberlein T et al. Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 1993;11:44-48.

  15. Rodriguez de Paterna L, Arnaiz F, Estenoz J et al. Study of serum markers CEA, CA 15-3 y CA 27-29 as diagnostic parameters in patients with breast carcinoma. Int J Biol Markers 1995;10:24-29.

  16. Stenman UH, Heikkein R. Serum markers for breast cancer. Scand J Clin Lab Invest 1991;206:52-59.

  17. Haga S, Watanabe O, Shimizu T et al. The clinical value of tissue carcinoembryonic antigen in breast cancer. Japan J Surg 1991;21:278-83.

  18. Andreoli C, Buranelli F, Campa T et al. Chest X-ray survey in breast cancer follow-up: a contrary view. Tumori 1987;73:463-5.

  19. Rutgers EJ, van Stooten E, Kluk HM. Follow-up after treatment of primary breast cancer. Br J Surg 1989;76:187-90.

  20. Wickerman L, Fisher B, Cronin W. The efficacy of bone scanning in the follow-up of patients with operable breast cancer. Breast Cancer Res Treat 1984;4:303-7.

  21. Viachos L, Trakadas S, Gouliamos A, et al. Comparative study between ultrasound, computed tomography, and magnetic resonance imaging in the differentiation of tumors of the liver. Gastrointest Radiol 1990;15:102-6.

  22. NOM (Norma Oficial Mexicana de Enfermedades Mamarias). México, 2005.

  23. Sociedad Mexicana de Oncología, Consenso sobre cáncer mamario (Cárdenas SJ, Sandoval GF). Colima, México, 2005.




2020     |     www.medigraphic.com